Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v3.24.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Jun. 30, 2023
Current assets:    
Cash and cash equivalents $ 130,132 $ 180,571
Short-term available-for-sale investments 5,520 23,739
Accounts receivable, less allowance for doubtful accounts of $3,502 and $4,738, respectively 207,451 218,468
Inventories 180,839 171,638
Current assets held-for-sale 26,647  
Other current assets 40,051 27,066
Total current assets 590,640 621,482
Property and equipment, net 234,204 226,200
Right of use assets 100,863 98,326
Goodwill 980,082 872,737
Intangible assets, net 550,605 534,645
Other assets 274,359 285,302
Total assets 2,730,753 2,638,692
Current liabilities:    
Trade accounts payable 31,514 25,679
Salaries, wages and related accruals 32,995 36,747
Accrued expenses 17,159 14,880
Contract liabilities 28,427 23,069
Income taxes payable 6,646 12,022
Operating lease liabilities - current 12,672 11,199
Contingent consideration payable   3,500
Current liabilities held-for-sale 1,593  
Other current liabilities 4,225 1,413
Total current liabilities 135,231 128,509
Deferred income taxes 71,575 88,982
Long-term debt obligations 447,000 350,000
Operating lease liabilities 96,027 93,766
Other long-term liabilities 17,361 10,919
Bio-Techne's Shareholders' equity:    
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding 0 0
Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 157,142,004 and 157,641,914 respectively 1,571 1,576
Additional paid-in capital 764,273 721,543
Retained earnings 1,261,376 1,309,461
Accumulated other comprehensive loss (63,661) (66,064)
Total Bio-Techne's shareholders' equity 1,963,559 1,966,516
Total liabilities and shareholders' equity $ 2,730,753 $ 2,638,692